BostonGene AI Models to Headline 2026 RadMed Oncology Symposium

BostonGene brings its next-generation AI foundation models for precision immuno-oncology to San Diego's premier industry-academia oncology gathering on June 11, 2026, underscoring the company's expanding role in reshaping cancer drug development.

Lead

BostonGene, the precision oncology AI company, will feature its next-generation AI foundation models at the 22nd Annual Industry/Academia Precision Oncology & RadMed Symposium on Thursday, June 11, 2026, at The Alexandria at Torrey Pines Conference Center in San Diego, California. The presentation, delivered by Michael F. Goldberg, PhD, VP of R&D, will demonstrate how the company's omnimodal platform integrates data across molecular, tissue, cellular, and patient levels to generate deep biological insights and accelerate oncology drug development.

What Happened

BostonGene is presenting at a gathering organized by Moores Cancer Center that convenes global leaders in life sciences across four focus domains: AI, immuno-oncology, radioligand therapies, and small molecule research. The full-day event runs from 8:00 a.m. to 6:30 p.m.

The session will showcase how BostonGene's AI foundation models synthesize multimodal oncology and immunology data — combining genomic and transcriptomic signals with tumor microenvironment profiling, circulating-free RNA detection, and real-world clinical outcomes — to generate what the company describes as biologically grounded intelligence. The system is trained on billions of data points spanning multiple oncology indications and produces high-dimensional embeddings that improve prediction of immunotherapy response and toxicity profiles.

AI and Technology Angle

At the core of BostonGene's platform is an omnimodal AI foundation model of tumor and immune biology. Unlike single-modality approaches, the architecture integrates pre-trained representations across data layers — from cell-free RNA and spatial transcriptomics to immune cell phenotyping — enabling dynamic, longitudinal prediction of treatment response and resistance in heterogeneous tumors.

The platform has demonstrated clinical utility across multiple cancer types, including breast cancer, kidney cancer, and hepatocellular carcinoma. In a study published in Cell Reports Medicine, BostonGene's multimodal AI stratified PD-1 and VEGF immunotherapy outcomes in renal cell carcinoma, establishing a pathway for data-driven patient selection in checkpoint inhibitor trials.

Blood-based profiling capabilities further allow real-time monitoring across treatment cycles, enhancing cohort design, accelerating clinical timelines, and strengthening regulatory submissions without reliance on repeat invasive biopsies.

Strategic Context

The RadMed appearance is part of an accelerating public presence for BostonGene in 2026. In May, the company announced a strategic collaboration with AstraZeneca to apply its foundation model-driven platform to early oncology clinical trials, with a focus on improving decision-making around patient safety, efficacy, and biomarker strategy. The partnership targets the industry's most costly problem: clinical trial failure from unpredictable patient response, which accounts for a significant share of late-stage drug development attrition.

Also in May, Frost & Sullivan named BostonGene its 2026 Global Company of the Year in AI-Driven Multimodal Oncology Platforms, citing the company's ability to translate complex biological data into decisions that directly impact patient selection and therapeutic strategy.

BostonGene also presented 13 abstracts at the American Association for Cancer Research Annual Meeting 2026 and demonstrated its disease modeling platform at JSMO 2026 in Japan, where Hokkaido University is among institutions leveraging the AI-powered system for precision oncology research.

What Comes Next

The RadMed session positions BostonGene among a cohort of AI-driven oncology companies moving from research partnerships into integrated drug development infrastructure. With AstraZeneca deploying its platform across an active portfolio and academic institutions in Japan, the United States, and elsewhere adopting its tools, the company is building the kind of multi-site clinical evidence base that supports regulatory adoption and broader pharmaceutical licensing.

Outlook

BostonGene's appearance at the 2026 RadMed Symposium reflects a pivotal moment in precision immuno-oncology, as AI foundation models transition from experimental research tools to core components of clinical trial design and patient stratification. The company's accumulation of partnerships, peer-reviewed publications, and industry recognition across the first half of 2026 signals a deepening institutional confidence in multimodal AI as a decision-support layer for oncology drug development. Mentioned tickers: AZN

Technology